TB-500 FAQ: Common Questions Answered with Research

TB-500 is one of the most asked-about peptides in the recovery and tissue-repair conversation, and most of what circulates online is anecdotal. This FAQ collects the questions people actually search for and answers them in plain language — grounded in the published research, the chemistry of thymosin beta-4, and how 503A compounding pharmacies actually handle the product.

Greenstone Peptides supplies TB-500 through licensed U.S. 503A compounding pharmacies, sterile-filled and third-party tested. The notes below are educational and intended to help you ask better questions of your prescribing clinician — not a substitute for that conversation.

What is TB-500?

TB-500 is a synthetic peptide fragment derived from thymosin beta-4, a 43-amino-acid protein found in nearly every human cell. The fragment reproduces a key bioactive sequence of the parent molecule — the region most associated in the literature with actin binding and cell migration. It is typically supplied as a lyophilized (freeze-dried) powder for reconstitution and subcutaneous injection in research settings.

Is TB-500 the same as thymosin beta-4?

Not quite. Thymosin beta-4 is the full 43-amino-acid native protein. TB-500 is a synthetic fragment that contains a key active region of that protein. In research papers the two are often discussed together because their proposed mechanisms — actin sequestration, cell migration, and angiogenesis — overlap. Most products marketed in the U.S. as TB-500 are the fragment, supplied lyophilized for stability.

What does the research actually show?

The published evidence base for TB-500 / thymosin beta-4 is primarily preclinical — animal models and in vitro work. Studies have explored wound healing, post-infarction cardiac repair, equine tendon and muscle injury, corneal healing, and neurological repair, with consistent reports of accelerated cell migration, angiogenesis, and reduced inflammatory signaling.

Human clinical trial data is far more limited than the animal-model literature, and that distinction matters. Outcomes from rodent or equine models should not be presented as proven human outcomes — they are signals, not endpoints.

How is TB-500 different from BPC-157?

TB-500 and BPC-157 are frequently grouped as "recovery peptides," but they are mechanistically distinct. TB-500 is associated primarily with actin binding, cell migration, and angiogenesis derived from thymosin beta-4 biology. BPC-157 is a 15-amino-acid peptide derived from a gastric protective protein and is most heavily studied in gastrointestinal mucosa, tendon, and ligament models. Some users discuss stacking the two; the published literature does not clearly establish a synergy beyond what each shows individually.

How is TB-500 stored and reconstituted?

Lyophilized TB-500 is stored refrigerated and away from direct light prior to reconstitution. After reconstitution with bacteriostatic water (0.9% benzyl alcohol), the solution is generally kept refrigerated and used within a defined window — commonly several weeks, depending on the formulation. These are general best practices for lyophilized peptides; the specific dilution volume and storage window should be confirmed with the prescribing pharmacy.

What is 503A compounding, and how does it apply to TB-500?

503A refers to the section of the Federal Food, Drug, and Cosmetic Act that governs traditional compounding pharmacies — facilities that prepare individualized prescriptions for specific patients. Greenstone's TB-500 is compounded in U.S. 503A facilities, sterile-filled under USP 797 conditions, and paired with third-party purity testing. The 503A pathway is the legitimate U.S. framework for prescription peptide products that are not commercially available as FDA-approved drugs.

Is TB-500 FDA-approved?

TB-500 is not an FDA-approved drug. It is a research peptide dispensed in the U.S. through 503A compounding pharmacies on patient-specific prescriptions. That is a distinct regulatory category from FDA-approved pharmaceutical products and should be understood as such when evaluating any source.

Can competitive athletes use TB-500?

TB-500 / thymosin beta-4 is listed by the World Anti-Doping Agency (WADA) as a prohibited substance, both in and out of competition. Athletes subject to WADA-aligned testing programs — Olympic, NCAA, and most professional leagues that defer to WADA standards — should treat it as banned and confirm specifics with their governing body before any decision.

How is TB-500 typically dosed in research?

Greenstone does not publish dosing protocols. The literature uses a wide range of dosing schedules across animal models, and human dosing — where it is discussed — is highly individualized. Any dosing decision should be made with a licensed clinician who can weigh the research base, the individual's clinical context, and the regulatory environment.

How can I tell if a TB-500 source is legitimate?

A legitimate U.S. source will operate through a licensed 503A compounding pharmacy, require a valid prescription, and provide third-party testing documentation. Domestic sourcing of the active pharmaceutical ingredient, sterile-fill in ISO-classified cleanrooms, and clear shipping protocols (cold-chain where appropriate) are additional quality signals. Vendors selling "research only" peptides without prescription oversight, lab work, or pharmacy licensure sit outside that framework — and the gap shows up in quality.

Bottom Line

TB-500 is a research peptide with a deep preclinical literature, a more limited human dataset, and a clear regulatory home in 503A compounding. Treated with that framing — and discussed with a clinician — it is a substance you can evaluate carefully rather than chase on hype.

Greenstone Peptides content is educational and does not constitute medical advice. Peptide therapies should be discussed with a licensed healthcare provider.